LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close trading update for the six months ended 31 July 2020 (“H1”), ahead of its interim results which are expected to be announced on 13 October 2020.
LiDCO (AIM: LID), the hemodynamic monitoring company, announces its audited Final Results for the year ended 31 January 2020 (“FY20”). The Group has achieved strong year-on-year growth in sales of LiDCO products with the development of a strong recurring revenue base through its Software as a Service (“SaaS”) High Usage Programme (“HUP”) business model.
LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close update in respect of its performance for the full year ended 31 January 2020 (“FY20”).
LiDCO (AIM: LID), the hemodynamic monitoring company, announces its unaudited Interim Results for the six months ended 31 July 2019.
LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following trading update for the six months ended 31 July 2019.
LiDCO (AIM: LID), the hemodynamic monitoring company, announces its audited Final Results for the year ended 31 January 2019.
LiDCO (AIM: LID), the hemodynamic monitoring company, announces the appointment of Tim Hall to the Board as Chief Financial Officer (CFO) and Company Secretary with effect from 11 March 2019.
LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close update for the full year ended 31 January 2019 (FY19).
LiDCO (AIM: LID), the hemodynamic monitoring company, announces an update on trading and outlook for the 12 month period ending 31 January 2019.
LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has had further success in the USA, contracting three additional customers to its recently launched differentiated High Usage Programme (HUP) business model.